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cartilage degradation by directly injecting chemically modulated siR-
NAs to surgically induced murine OA knee joints. Our hypothesis was
that effective RNAi could be achieved by injection of highly concen-
trated siRNA in the knee joint, resulting in reduced development of
osteoarthritis.
Methods: Knee OAs were surgically induced to C57BL/6 mice by
destabilization of the medial meniscus (DMM) method, by trans-
ecting the medial meniscotibial ligament under general anesthesia.
To determine the timing of protease expressions in the murine DMM
induced OA model, messenger RNA (mRNA) of MMP13 from knee
cartilage were analyzed at 3 days, 1 week, 2 weeks, 4 weeks, and 6
weeks after surgery by quantitative polymerase chain reaction
(qPCR).
One week after DMM induction, chemically modulated siRNAs were
injected in the knee joint. Two different content of injection were
evaluated. Treatment groups consisted of a group which MMP13 siRNA
was injected, and another group in which control siRNA was injected.
The control siRNAwas conﬁrmed not to affect MMP13 in vitro. The RNAi
effects were assessed by quantifying MMP13 mRNA in knee cartilage at
48 hours after siRNA injection. Histological assessment of articular
cartilage at 8 weeks post DMM operation was conducted to assess the
effect of siRNA injection at one week after DMM in osteoarthritis
progression, according to the OARSI recommendation for OA knee
scoring in mice.
Results: Surgically induced OAs were successfully achieved in
the DMM model of mice. MMP13 expressions elevated from the
third post operative day, and peaked in a week after DMM surgery
(Fig. 1). Expression level of MMP13 mRNA was signiﬁcantly
decreased at 48 hours after injection of MMP13 siRNA to the knee
joint, compared to negative control siRNA injection (Fig. 2).
Signiﬁcant improvement was observed in the histological score of
MMP siRNA treated group, compared to the control siRNA injected
group.
Conclusions: Direct injection of siRNAs targeting MMP13 at the early
phase of OA development has the potential to inhibit protease expres-
sion and inhibits cartilage degradation in vivo.ĂĂ34
FIVE TO TEN YEAR FOLLOW UP OF MATRIX ASSOCIATED
AUTOLOGOUS CHONDROCYTE TRANSPLANTATION (MACT) IN THE
KNEE
M. Brix 1, C. Chiari 1, S. Nehrer 2, R. Windhager 1, S. Domayer 1. 1Med.
Univ. of Vienna, Vienna, Austria; 2Danube Univ. Krems, Krems, Austria
Purpose: Compared to the original autologous cartilage transplantation
technique, matrix associated autologous cartilage transplantation
(MACT) techniques, as a possibility of cartilage repair technique, have
achieved comparable outcome at mid-term, but there is still a lack of
long-term results. The goal of this study was to obtain ﬁrst results after
10 years in a MACT technique in the knee.
Methods: A total number of 53 (22 female, 31 male) patients with
articular cartilage lesions of the knee were included in this prospective
case series. The average age ( SD) at implantation was 32  12 years
and the average Body Mass Index (BMI) was 24.5  3.8 kg/m2. The
average defect size was 4.4  1.9 cm2 (50 single defects, 3 patients with
multiple defects). All defects were classiﬁed as Outerbridge III or IV.
Primary indications (42 patients) were a stable joint, normal knee
alignment, isolated chondral defects with otherwise healthy adjacent
cartilage and age < 55 years. Secondary indications (11 patients) were
not fulﬁlling the primary indication criteria or were salvage procedures.
Four clinical scores (subjective IKDC knee form, Lysholm score, the
patient perception scale of the Cincinnati knee rating system, objective
IKDC knee form) were obtained for clinical evaluation. All patients were
treated with Hyalograft C.
Results: Altogether, 3 of 53 patients reached the 10-year follow up to
this day. In this study group, we depicted a signiﬁcant increase in the
Cincinnati patient perception scale when compared to pre surgery
scores(2.9 vs. 8.0; p<0.01). The 8-year follow up group showed
signiﬁcant differences in the Lysholm score (57.4 vs. 83.4; p<0.01), the
IKDC subjective score (49.3 vs. 67.8; p<0.05) and the Cincinnati
patient perception scale (2.1 vs. 7.4; p<0.01). Graft failure occurred in
3 of 42 patients with primary indications and 9 of 11 patients with
secondary indications. The difference was statistically signiﬁcant
(p<0.001).
Conclusions: Our data suggests, that the promising short-term results
were also found at mid- and long-term in younger patients (< 40 years)
with stable joints, normal knee alignment and single defects. In
contrast, salvage cases did not proﬁt from the treatment.
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A PHASE IIA CLINICAL STUDY OF TISSUEGENE-C (TG-C) IN PATIENTS
WITH OSTEOARTHRITIS
C.-W.Ha 1, S.H. Park 2, J.J. Cho 2, T.W. Kim2,M.J. Noh 3,M.C. Lee 4. 1 Samsung
Med. Ctr., Seoul, Republic of Korea; 2Kolon Life Sci., GwaChun, Republic of
Korea; 3 TissueGene, Inc, Rockville, MD, USA; 4 Seoul Natl. Univ. Hosp.,
Seoul, Republic of Korea
Purpose: TG-C is a gene and cell therapy for osteoarthritis that employs
ex vivo gene delivery via a retrovirally transduced, established line of
chondrocytes that overexpress transforming growth factor-b1 (TGF-b1).
TG-C contains normal (hChonJ) and transduced (hChonJb#7) chon-
drocytes by the ratio of 3:1. The hChonJ cells are normal allogeneic
chondrocytes and the hChonJb#7 cells are chondrocytes transduced
with TGF-b1 gene-containing retroviral vector, and further treated with
gamma-ray irradiation to limit their survival for up to 2 weeks in
patients. The gamma-ray irradiation was designed to render them
incapable of cell division and therefore to eliminate any possibility of
these cells causing cancer. Phase I study has demonstrated that no
severe adverse events (SAEs) were observed and dose limiting toxicity
was not observed up to the dose level of 3x107 cells/knee.
Methods: In the current study, the randomized and single blind phase
IIa trials were conducted to determine both safety and efﬁcacy in
patients with knee osteoarthritis. Participants (n ¼ 27, 21 females and
6 males) with a conﬁrmed diagnosis of knee osteoarthritis by MRI
were randomized to either 0.6x107 cells/knee (low dose group, n ¼ 13,
mean age of 60.467.50 year) or 1.8x107 cells/knee (high dose group,
n ¼ 14, mean age of 58.29  6.94 year) of TG-C treatment. The
primary evaluation was International Knee Document Committee
(IKDC) which is comprised of three sub-scales: pain, sports activities,
and daily function. The secondary evaluations were Western-Ontario
and MacMaster University (WOMAC) score and 100 mm Visual
Analogue Scale (VAS). These parameters were evaluated at 12, 24 and
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replication competent retrovirus (RCR), retrovirally transduced cells
and TGF-b1 protein starting from 2 weeks up to 6 months post
treatment. Safety measures including physical exams, complete blood
count, and serum chemistry were included up to 6 months post
treatment.
Results: TG-C signiﬁcantly improved IKDC, WOMAC, and 100 mm VAS
scores. Low and high doses of TG-C treatment showed signiﬁcant
improvement in total IKDC score by 33% (from 44.9  7.8 to 59.93 
10.5, p<0.001) and by 25% (from 49.9 2  9.5 to 62.48  9.7, p<0.001),
respectively, at 6 month post treatment. Low and high doses of TG-C
treatment showed signiﬁcant improvement in WOMAC scores by 45%
(from 31.92  8.4 to 17.43  8.2, p<0.001) and by 41% (from 30.00  9.5
to 17.79  9.7), respectively, at 6 month post treatment. Low and high
doses of TG-C treatment also improved 100mmVAS scores from by 47%
(51.07  13.4 to 26.50  14) and by 45% (from 50.77  13.3 to 28.14
11.2), respectively, at 6 month post treatment. No SAEs were shown in
the treatment groups.
Conclusions: The current phase IIa study indicated that TG-C improved
three evaluation criteria for pain, sports activities, and quality of daily
life in patients with osteoarthritis without showing SAEs.
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THE INTENSIVE DIET AND EXERCISE FOR ARTHRITIS TRIAL (IDEA):
EFFECTS ON KNEE JOINT LOADING AND INFLAMMATION
S.P. Messier 1, P. DeVita 2, B.J. Nicklas 3, D. Beavers 3, S. Mihalko 1,
G.D. Miller 1, M. Lyles 3, D.J. Hunter 4, F. Eckstein 5, C. Legault 3,
J.D. Williamson 3, J.J. Carr 3, R.F. Loeser 3. 1Wake Forest Univ., Winston-
Salem, NC, USA; 2 East Carolina Univ., Greenville, NC, USA; 3Wake Forest
Univ. Sch. of Med., Winston-Salem, NC, USA; 4Univ. of Sydney, Sydney,
Australia; 5 Paracelsus Med. Univ., Salzburg, Austria
Purpose: Overweight and obesity is the most modiﬁable risk factor for
symptomatic knee osteoarthritis (OA), and dietary induced weight loss
combined with exercise is potentially the best non-pharmacologic
treatment. We report the mechanistic primary outcomes of a long-term
(18 month) study designed to test the hypothesis that intensive weight
loss, either with or without exercise, will reduce knee joint loads and
serum levels of inﬂammatory biomarkers compared to an exercise only
control group in older, overweight and obese adults with symptomatic
knee OA.
Methods: The Intensive Diet and Exercise for Arthritis trial (IDEA) was
a prospective, single-blind, randomized controlled trial that enrolled
454 overweight and obese (BMI ¼ 27-40.5 kg/m2) older (age  55 yrs)
adults with pain and radiographic evidence of tibiofemoral OA (KL ¼
2-3). Participants were randomized to one of three 18-month inter-
ventions: intensive dietary restriction-only (D); intensive dietary
restriction-plus-exercise (D+E); or exercise-only control (E). The
weight loss goal for the two diet groups was  10% of baseline body
weight. The exercise intervention consisted of low to moderate
intensity walking and resistance training 3 d/wk for 1 hr/d. High
speed motion analysis and musculoskeletal modeling were used to
calculate knee joint loads, and fasting serum concentrations of
inﬂammatory biomarkers were measured by enzyme-linked immu-
nosorbent assays. We used an intention-to-treat analysis to compare
differences between groups in changes from baseline (at 6 and 18
month follow-up combined) after adjusting for gender, baseline BMI,
visit (6 and 18 months), and baseline values of the dependent variable
using repeated measures ANCOVA.
Results: Mean baseline descriptive characterisitics of the cohort
included: age, 65.6 yrs.; BMI, 33.6 kg/m2; 72%female; 81%white. A
total of 399 (88%) participants completed the study and returned for
FU18 testing. Mean weight loss was: D, 9.5%; D+E, 11.4%; E, 2.2%.
Mean (SE) IL-6 (pg/mL), the primary inﬂammatory outcome, was
signiﬁcantly changed in the D, -0.43 (0.11) and D+E, -0.36 (0.11)
groups compared to the E, 0.04 (0.11) group (p ¼ 0.005). Similarly,
Leptin (ng/mL) also signiﬁcantly changed in the D, -13 (2) and D+E,
-14 (1) groups relative to the E, -3 (1) group (p < 0.0001). Knee
compressive force (N/step), the primary mechanical outcome, was
signiﬁcantly reduced in the D, -174 (42) and D+E, -51 (40) groups
compared to the E, 154 (41) group (p < 0.0001). Results from the
musculoskeletal model revealed that the differences in knee
compressive forces were associated to signiﬁcant changes (N/step)
in hamstring muscle force (D, -56 (18); D+E, 3 (17); E, 71 (17):
p < 0.0001), gastrocnemius force (D, -43 (6); D+E, -39 (5); E, 12 (5):p < 0.0001), and quadriceps forces (D, -46 (28); D+E, 27 (26); E, 121
(27): p < 0.0001). Changes in the peak internal abductor moment
(Nm), a commonly used surrogate of medial compartment joint
loading, were not different between the groups (D, 0.33 (0.72); D+E,
1.51 (0.69); E, 0.49 (0.70): p ¼0.4), primarily due to heterogeneity in
frontal plane knee alignment among the participants.
Conclusions:This trial shows that intensive weight loss, with or
without exercise, signiﬁcantly impacts both the mechanical and
inﬂammatory OA disease pathways by reducing knee joint compressive
loads and IL-6, respectively. While exercise is effective in improving
clinical outcomes in this population, our data indicate that intensive
weight loss, not exercise, is the non-pharmacologic treatment that
signiﬁcantly impacts both OA disease pathways.
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EFFICACY AND SAFETY OF LONG-TERM REPEATED, INTRA-
ARTICULAR INJECTIONS OF HYALURONIC ACID IN KNEE
OSTEOARTHRITIS: FINAL RESULTS OF THE AMELIA TRIAL
F. Navarro-Sarabia 1, P. Coronel 2, F. Blanco 3, A. Rodriguez de la
Serna 4, M. Gimeno 2, G. Herrero-Beaumont 5. on behalf of AMELIA
study group1Hosp. Virgen Macarena, Sevilla, Spain; 2 Tedec Meiji Farma
SA, Alcalá de Henares, Spain; 3Hosp. Juan Canalejo, La Coruña, Spain;
4Hosp. Santa Creu i Sant Pau, Barcelona, Spain; 5 Fundación Jiménez
Díaz, Madrid, Spain
Purpose: A clear picture about the beneﬁts of repeated courses of
Hyaluronic Acid (HA) on osteoarthritis (OA) is pending to be drawn.
AMELIA (Arthrosis Modifying Effects of Long-term Intra-articular
Adant) is a recently completed multicentre, double-blind, placebo-
controlled clinical trial with a 40 months follow-up to assess the efﬁ-
cacy and tolerability of repeated administration of intra-articular
injections of Adant or placebo in knee osteoarthritis.
Methods: Patients with primary knee osteoarthritis (ACR criteria),
radiological grades II-III according to Kellgren scale and joint space
width >¼2 mm were randomised 1:1 to receive 4 cycles of 5 intra-
articular Adant or placebo (saline) injections each one. The follow up
periods were 6 months long after the ﬁrst and second cycles and 1
year long after the third and fourth ones making total study duration
of 40 months (Figure 1). OMERACT-OARSI 2004 responder criteria
were used for efﬁcacy evaluation. Adverse events were recorded for
safety purposes and monitored until resolution.).
Results: From 446 screened, a total of 306 patients were randomized
and allocated to Adant or placebo. Both groups were homogeneous at
baseline for demographics and OA characteristics (see ARD Nov 2011 for
further details) and a total of 203 patients completed the study
procedures.
At the end of follow-up, signiﬁcantly more patients receiving Adant
responded to treatment in comparison to placebo according to OMER-
ACT-OARSI 2004 criteria (p¼0.004), the number of responders being
22% higher in HA group (RR 1.22; CI 95% 1.07 to 1.41). Signiﬁcant
differences were also found in favour of HA for each individual
component of the OMERACT-OARSI 2004: pain, function and patient
global assessment with p values of 0.025, 0.023 and 0.002 respectively.
Responders to HA injections progressively increased after each treat-
ment cycle (from 71.1% to 80.5%) whereas responders to placebo
remained fairly stable (from 67.8% to 65.8%) providing statistically
signiﬁcant differences between both groups through the study period
(Figure 2). Dropouts due to lack of efﬁcacy were statistically signiﬁcant
lower in HA group (p¼0.026). Paracetamol was consumed by 48% of the
patients and the mean daily dose during the study experienced a 27%
reduction in the HA group compared to baseline versus only a 4% in the
placebo group.
Twenty-two patients (11 per group) experienced a total of 29 related
adverse events, the rate of related adverse events/cycle being 0.029 in
both groups. Most of them were related with the study intervention,
such as local bleeding, pain of mild intensity or allergic reaction and
none of them serious.
Conclusions: AMELIA trial evidence the superiority of Adant to
placebo. Repeated cycles of intra-articular injections of this HA not only
improve knee OA symptoms during the in-between cycle period, but
also exert a marked carry over effect lasting for at least one year after
the last cycle. Adverse reactions were scarce and related to the
administration procedure.
